Multitarget drugs: the present and the future of cancer therapy - PubMed (original) (raw)
Review
Multitarget drugs: the present and the future of cancer therapy
Annalisa Petrelli et al. Expert Opin Pharmacother. 2009 Mar.
Abstract
Target therapies for the treatment of human cancers have revolutionized the concept of oncological medicine. This type of therapeutic approach is directed to the inhibition of molecular targets that play a pivotal role in tumor progression -- such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival -- mainly by means of compounds able to block their activity. In the beginning, the aim of target therapies was specifically to hit a single molecule expressed in neoplastic cells. Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease. Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different molecules. This review summarizes the molecular basis of multitarget therapies and the most relevant results obtained in different cancer types.
Similar articles
- Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Bavcar S, Argyle DJ. Bavcar S, et al. Vet Comp Oncol. 2012 Sep;10(3):163-73. doi: 10.1111/j.1476-5829.2012.00342.x. Vet Comp Oncol. 2012. PMID: 22882485 Review. - Researchers optimistic about sea change in cancer treatment.
Stephenson J. Stephenson J. JAMA. 2001 Jun 13;285(22):2841-2. doi: 10.1001/jama.285.22.2841. JAMA. 2001. PMID: 11401587 No abstract available. - Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
Camorani S, Crescenzi E, Fedele M, Cerchia L. Camorani S, et al. Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):263-277. doi: 10.1016/j.bbcan.2018.03.003. Epub 2018 Mar 21. Biochim Biophys Acta Rev Cancer. 2018. PMID: 29574128 Review. - Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
Roussidis AE, Karamanos NK. Roussidis AE, et al. In Vivo. 2002 Nov-Dec;16(6):459-69. In Vivo. 2002. PMID: 12494890 Review. - Receptor tyrosine kinases: the main targets for new anticancer therapy.
Drevs J, Medinger M, Schmidt-Gersbach C, Weber R, Unger C. Drevs J, et al. Curr Drug Targets. 2003 Feb;4(2):113-21. doi: 10.2174/1389450033346885. Curr Drug Targets. 2003. PMID: 12558064 Review.
Cited by
- Computer-Aided Identification and Design of Ligands for Multi-Targeting Inhibition of a Molecular Acute Myeloid Leukemia Network.
Asfa SS, Arshinchi Bonab R, Önder O, Uça Apaydın M, Döşeme H, Küçük C, Georgakilas AG, Stadler BM, Logotheti S, Kale S, Pavlopoulou A. Asfa SS, et al. Cancers (Basel). 2024 Oct 25;16(21):3607. doi: 10.3390/cancers16213607. Cancers (Basel). 2024. PMID: 39518047 Free PMC article. - Development of Novel Alaninamide Derivatives with Anticonvulsant Activity and Favorable Safety Profiles in Animal Models.
Abram M, Jakubiec M, Koczurkiewicz-Adamczyk P, Doroz-Płonka A, Rapacz A, Kamiński K. Abram M, et al. Int J Mol Sci. 2024 Sep 12;25(18):9861. doi: 10.3390/ijms25189861. Int J Mol Sci. 2024. PMID: 39337345 Free PMC article. - Discovery and Profiling of New Multimodal Phenylglycinamide Derivatives as Potent Antiseizure and Antinociceptive Drug Candidates.
Jakubiec M, Abram M, Zagaja M, Socała K, Panic V, Latacz G, Mogilski S, Szafarz M, Szala-Rycaj J, Saunders J, West PJ, Nieoczym D, Przejczowska-Pomierny K, Szulczyk B, Krupa A, Wyska E, Wlaź P, Metcalf CS, Wilcox K, Andres-Mach M, Kamiński RM, Kamiński K. Jakubiec M, et al. ACS Chem Neurosci. 2024 Sep 4;15(17):3228-3256. doi: 10.1021/acschemneuro.4c00438. Epub 2024 Aug 21. ACS Chem Neurosci. 2024. PMID: 39166702 Free PMC article. - Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies─In Vitro and In Vivo Characterization.
Jakubiec M, Abram M, Zagaja M, Andres-Mach M, Szala-Rycaj J, Latacz G, Honkisz-Orzechowska E, Mogilski S, Kubacka M, Szafarz M, Pociecha K, Przejczowska-Pomierny K, Wyska E, Socała K, Nieoczym D, Szulczyk B, Wlaź P, Metcalf CS, Wilcox K, Kamiński RM, Kamiński K. Jakubiec M, et al. ACS Chem Neurosci. 2024 Jun 5;15(11):2198-2222. doi: 10.1021/acschemneuro.4c00013. Epub 2024 May 14. ACS Chem Neurosci. 2024. PMID: 38741575 Free PMC article. - Therapeutic potential of EGFR/mTOR/Nf-kb targeting small molecule for the treatment of non-small cell lung cancer.
Lawal B, Kuo YC, Wu AT, Huang HS. Lawal B, et al. Am J Cancer Res. 2023 Jun 15;13(6):2598-2616. eCollection 2023. Am J Cancer Res. 2023. PMID: 37424807 Free PMC article.